Early Onset Alzheimer's Disease Genomic Study (TGen)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03645993|
Recruitment Status : Unknown
Verified October 2019 by Baylor Research Institute.
Recruitment status was: Recruiting
First Posted : August 24, 2018
Last Update Posted : October 7, 2019
|Condition or disease||Intervention/treatment|
|Alzheimer Disease||Genetic: Genetic Testing|
|Study Type :||Observational|
|Estimated Enrollment :||2 participants|
|Official Title:||Early Onset Alzheimer's Disease Genomic Study|
|Actual Study Start Date :||June 16, 2017|
|Estimated Primary Completion Date :||June 16, 2022|
|Estimated Study Completion Date :||June 16, 2022|
Early-Onset Alzheimer's disease
Patients ages 45-60 with Early-Onset Alzheimer's disease
Genetic: Genetic Testing
A one time blood sample will be taken.
Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
- Biomarkers found in blood [ Time Frame: 2 years ]Blood will be taken so that tests can be run to locate a biomarker that will help to diagnose and treat early-onset Alzheimer's disease.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03645993
|Contact: Sarah B Burris, MHA||214-818-0382||Sarah.Burris@BSWHealth.org|
|United States, Texas|
|Baylor Scott & White AT&T Memory Center||Recruiting|
|Dallas, Texas, United States, 75231|
|Contact: Sarah B Burris, MHA|